Association of PET‐based stages of amyloid deposition with neuropathological markers of Aβ pathology
Abstract
To determine if PET‐based stages of regional amyloid deposition are associated with neuropathological phases of Aβ pathology.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 02, 2020
- Source ID
- 10.1002/acn3.51238
Entities
People
- Anna G M Temp
- Fedor Levin
- Martin Dyrba
- Michel J. Grothe
- Stefan J Teipel
- The Alzheimer’s Disease Neuroimaging Initiative*
Organizations
- BioClinica
- Biogen
- Bristol-Myers Squibb
- Canadian Institutes of Health Research
- Chiron Corporation
- Eli Lilly and Company
- Foundation for the National Institutes of Health
- GE HealthCare
- German Center for Neurodegenerative Diseases
- Hoffmann-La Roche
- Innogenetics
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Northern California Institute for Research and Education
- Pfizer
- Roche (United States)
- Rostock Medical Faculty
- Spanish National Research Council
- Takeda Pharmaceutical Company
- United States Department of Defense